Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women

被引：0
|
作者：
Amanda I. Phipps
Karen W. Makar
Polly A. Newcomb
机构：
[1] Fred Hutchinson Cancer Research Center,Public Health Sciences Division
[2] Fred Hutchinson Cancer Research Center,Public Health Sciences Division
来源：
International Journal of Colorectal Disease | 2013年 / 28卷
关键词：
Colorectal cancer; PIK3CA; Survival; KRAS;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1637 / 1642
页数：5
相关论文
共 50 条
  • [21] FDA Approves Inavolisib Combo for PIK3CA-Mutated, HR plus Breast Cancer
    Zhang, Jinwei
    CURRENT MEDICINAL CHEMISTRY, 2025,
  • [22] Outcome and mutational landscape of patients with PIK3CA-mutated metastatic breast cancer (mBC)
    Mosele, M. F.
    Lusque, A.
    Dien, A. Tran
    Droin, N.
    Le Tourneau, C.
    Lacroix, L.
    Bieche, I.
    Massard, C.
    Bertucci, F.
    Andre, F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [23] Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
    Andre, Fabrice
    Ciruelos, Eva
    Rubovszky, Gabor
    Campone, Mario
    Loibl, Sibylle
    Rugo, Hope S.
    Iwata, Hiroji
    Conte, Pierfranco
    Mayer, Ingrid A.
    Kaufman, Bella
    Yamashita, Toshinari
    Lu, Yen-Shen
    Inoue, Kenichi
    Takahashi, Masato
    Papai, Zsuzsanna
    Longin, Anne-Sophie
    Mills, David
    Wilke, Celine
    Hirawat, Samit
    Juric, Dejan
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20): : 1929 - 1940
  • [24] Einsatz von Alpelisib beim fortgeschrittenen PIK3CA-mutierten MammakarzinomUse of alpelisib for PIK3CA-mutated advanced breast cancer
    Wolfram Malter
    Hakan Alakus
    Peter Mallmann
    Christiane Bruns
    Der Onkologe, 2019, 25 (8): : 724 - 725
  • [25] BYL719 (ALPELISIB) FOR THE TREATMENT OF PIK3CA-MUTATED, RECURRENT/ADVANCED CERVICAL CANCER
    Bogani, G.
    Bini, M.
    Ronzulli, D.
    Raspagliesi, F.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A12 - A12
  • [26] BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer
    Bogani, Giorgio
    Chiappa, Valentina
    Bini, Marta
    Ronzulli, Dominique
    Indini, Alice
    Conca, Elena
    Raspagliesi, Francesco
    TUMORI JOURNAL, 2023, 109 (02): : 244 - 248
  • [27] Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives
    Chang, Dwan-Ying
    Ma, Wei-Li
    Lu, Yen-Shen
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2021, 17 : 193 - 207
  • [28] BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer
    Bogani, G.
    Indini, A.
    Bini, M.
    Raspagliesi, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S754 - S754
  • [29] Exceptional Response to Copanlisib in a Heavily Pretreated Patient With PIK3CA-Mutated Metastatic Breast Cancer
    Spathas, Nikolaos
    Economopoulou, Panagiota
    Kotsantis, Ioannis
    Oikonomopoulos, Nikolaos
    Psyrri, Amanda
    JCO PRECISION ONCOLOGY, 2020, 4 : 335 - 340
  • [30] Perifosine enhances the sensitivity to oxaliplatin and 5-fluorourasil in PIK3CA-mutated colon cancer
    Takefuji, Honoka
    Tsubaki, Masanobu
    Takeda, Tomoya
    Matsuda, Takuya
    Kimura, Akihiro
    Nishida, Shozo
    CANCER SCIENCE, 2023, 114 : 680 - 680
12345